Search results
Results from the WOW.Com Content Network
Gp100:209-217(210M) is a synthetic peptide cancer vaccine consisting of amino acid residues 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen, with a methionine substitution at position 210. [1] It is often referred to as the gp100 cancer vaccine which can also include other peptides based on gp100 (for example gp100:280-288(288V ...
Rindopepimut (CDX-110) is an injectable peptide cancer vaccine [1] which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. [2]The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope [3]) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH).
NeuVax is a peptide vaccine aimed at preventing or delaying the recurrence of breast cancer in cancer survivors who achieve remission after standard of care treatment (e.g., surgery, radiation, chemotherapy). [1] The product's developer is the US biotechnology company Galena Biopharma.
The peptides can be specially designed for specificity. A single peptide vaccine can be designed to have multiple epitopes to generate immune responses for several diseases. The vaccines only contain a short peptide chain, so they are less like to lead to allergic or auto-immune responses. Disadvantages: Poor immunogenicity. Unstable in cells.
Several DC-based cancer vaccines have been developed including DC loaded with, tumor peptides or whole proteins, [6] with tumor-derived mRNA or DNA., [7] DC transduced with viral vectors such as retroviruses, [8] lentiviruses [9] adenoviruses, [10] fowl pox [11] and alphaviruses containing the tumor antigen or gene of interest, whole necrotic ...
CimaVax-EGF is a vaccine used to treat cancer, specifically non-small-cell lung carcinoma (NSCLC). CIMAvax-EGF is composed of recombinant human epidermal growth factor (EGF) conjugated to a protein carrier. [2] The vaccine was developed by the Center of Molecular Immunology, Havana, Cuba, and made available to the Cuban population in 2011.
The duo have partnered since 2016 with a focus on cancer, where Merck is a dominant player for therapies, but the Phase 2 results are the first promising for a any cancer vaccine.
The production of vaccines tailored to match a person's individual constellation of cancer mutations has become a new field of research. [ 3 ] The concept of individualized cancer immunotherapy aims to identify individual mutations in the tumor of a patient, that are crucial for the proliferation, survival or metastasis of tumor cells. [ 2 ]